Characteristics | All Patients, n = 234 | No Flare Reported, n = 59 | Only Past Flares, n = 58 | Current Flare, n = 117 |
---|---|---|---|---|
Males | 169 (73.5) | 41 (70.7) | 37 (66.1) | 91 (78.4) |
Age, yrs, mean (SD) | 45.5 (11.8) | 47.0 (12.8) | 45.7 (11.7) | 44.7 (11.5) |
Time since AS onset, yrs, mean (SD) | 21.7 (11.7) | 23.0 (11.0) | 23.5 (13.7) | 20.2 (10.8) |
White | 206 (97.6) | 50 (98) | 52 (96.3) | 104 (98.1) |
Education above end of high school | 141 (61.3) | 37 (63.8) | 39 (69.6) | 65 (56.0) |
Paid employment | 176 (75.5) | 43 (72.9) | 46 (80.7) | 87 (74.4) |
History of extraarticular symptoms | ||||
Uveitis, psoriasis, and/or IBD | 116 (51.8) | 24 (41.4) | 30 (54.5) | 62 (55.9) |
Psoriasis | 37 (17.5) | 7 (12.7) | 13 (24.5) | 17 (16.5) |
Uveitis | 81 (37.2) | 16 (28.6) | 22 (39.3) | 43 (40.6) |
IBD | 42 (19) | 10 (17.2) | 11 (20.8) | 21 (19.1) |
Family history of AS | 69 (29.5) | 21 (35.6) | 13 (22.4) | 35 (29.9) |
Medication, previous month | ||||
NSAID | 220 (94.0) | 53 (89.8) | 55 (94.8) | 112 (95.7) |
csDMARD | 55 (23.5) | 11 (18.6) | 18 (31.0) | 26 (22.2) |
Anti-TNF | 18 (7.7) | 9 (15.3) | 7 (12.1) | 2 (1.7) |
BASDAI, mean (SD) | 4.4 (2.3) | 2.4 (1.7) | 4.0 (1.7) | 5.6 (2.0) |
BASFI, mean (SD) | 3.4 (2.6) | 1.7 (1.8) | 2.9 (2.4) | 4.6 (2.5) |
ASQoL, mean (SD) | 6.7 (5.5) | 2.5 (3.2) | 5.3 (4.5) | 9.5 (5.3) |
PASS, acceptable state | 135.0 (59.2) | 51.0 (89.5) | 46.0 (79.3) | 38.0 (33.6) |
axSpA: axial spondyloarthritis; AS: ankylosing spondylitis; IBD: inflammatory bowel disease; NSAID: nonsteroidal antiinflammatory drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; anti-TNF: antitumor necrosis factor; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ASQoL: AS Quality of Life; PASS: Patient-Acceptable Symptom State.